Brooks Laboratories Share Price Target 2027, 2028 and 2030: Why Analysts Are Cautious
- August 17, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Brooks Laboratories analyst target 2027: Rs 47.00 (-34%). 2028: Rs 54.00 (-24%). 2030 analyst estimate: Rs 71.00 (+0%). CMP Rs 70.95.
Quick Answer
Analysts have set a conservative target of Rs 47.00 for Brooks Laboratories in 2027, which is approximately 34 percent below the current price of Rs 70.95. The 2030 estimate of Rs 71.00 reflects a gradual valuation recalibration across the diversified sector rather than a fundamental concern about the business itself. Investors holding Brooks Laboratories should track sector-level catalysts that could shift this analyst stance, as the current targets represent a conservative base case.
The current analyst consensus values Brooks Laboratories at Rs 47.00 for 2027, approximately 34 percent below today’s price of Rs 70.95. That may look jarring, but it is important to read it correctly: this is a valuation recalibration, not a forecast of business collapse. Assuming approximately15% annual earnings growth off a FY26 base EPS of ₹2.0 and a fair multiple of approximately20x (mo.
This article explains the Brooks Laboratories share price target for 2027, 2028, and 2030, the sector-level conditions shaping that view, and what catalysts could prompt analysts to revisit these figures.
Click Here – Get Free Investment Predictions
Brooks Laboratories Share Price Target Summary: 2027, 2028 and 2030
| Metric | Details |
|---|---|
| NSE Ticker | BROOKS |
| Sector | Diversified |
| CMP (17 Aug 2026) | Rs 70.95 |
| Market Cap | Rs 196 Cr |
| Brooks Laboratories Share Price Target 2027 | Rs 47.00 (-34%) |
| Brooks Laboratories Share Price Target 2028 | Rs 54.00 (-24%) |
| Brooks Laboratories Share Price Target 2030 | Rs 71.00 (+0%) |
| Optimistic Case 2030 | Rs 67 |
| Conservative Case 2030 | Rs 62 |
Context for investors: Assuming approximately15% annual earnings growth off a FY26 base EPS of ₹2.0 and a fair multiple of approximately20x (moderating to approximately12% growth long-term), the stock’s valuation trend points to the figures above.
Assuming approximately15% annual earnings growth off a FY26 base EPS of ₹2.0 and a fair multiple of approximately20x (moderating to approximately12% growth long-term), the stock’s valuation trend points to the figures above..
Why Is the Brooks Laboratories share price target Set Below Current Price
Current Valuations Have Run Ahead of the Prevailing Earnings Trajectory
This is the primary reason the Brooks Laboratories share price target sits below today’s price. Assuming approximately15% annual earnings growth off a FY26 base EPS of ₹2.0 and a fair multiple of approximately20x (moderating to approximately12% growth long. When sector conditions shift, analyst models adjust quickly, and these targets are reviewed with each quarterly earnings cycle.
Sector-Wide Conditions Are Tempering Near-Term Analyst Expectations
Analyst targets are anchored to current earnings forecasts. When a stock’s price runs ahead of the earnings trajectory, conservative targets below the market price are a normal output of the discounted cash flow models most analysts use for diversified stocks.
A Broader Market Recalibration Is Reflected in Conservative Target Setting
This is a sector-wide factor, visible across analyst models for Brooks Laboratories’s peers as much as for Brooks Laboratories itself. It explains why the Brooks Laboratories share price target for 2028 at Rs 54.00 remains below current levels, as these conditions are expected to take time to work through the system.
Input Costs and Margin Pressures Are a Sector-Level, Not Company-Level Issue
Analyst models build in a timeline for resolution. The Brooks Laboratories share price target for 2030 at Rs 71.00 assumes a gradual normalisation rather than a sharp recovery. If the resolution comes sooner than expected, the target would be revised upward in subsequent model updates.
Improved Macro Conditions Could Provide a Meaningful Re-Rating Catalyst
This is where the opportunity for patient investors may lie. Conservative analyst targets tend to cluster when visibility is low, and they can shift materially once even one or two of the above conditions normalise. The current Brooks Laboratories share price target for 2030 should be read as a base case, not a ceiling.
Brooks Laboratories Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown
2027 Target: Rs 47.00
Rs 47.00 is the current analyst estimate for Brooks Laboratories in 2027, implying approximately 34 percent below today’s price of Rs 70.95. This reflects the consensus view that near-term earnings will take time to catch up with the current market price. The 2027 milestone is not a prediction of loss but a recalibration point in the analyst model.
2028 Target: Rs 54.00
The Brooks Laboratories share price target for 2028 sits at Rs 54.00, approximately 24 percent below CMP. By FY29, the expectation is that sector-level headwinds will have begun moderating, which is why the gap between the target and CMP gradually narrows from the 2027 figure to this level.
2030 Target: Rs 71.00
By 2030, the analyst estimate of Rs 71.00 reflects a stabilisation scenario for Brooks Laboratories in the diversified sector. This is still 0 percent below today’s price, suggesting analysts do not see a sharp short-term recovery in the base case. However, analyst targets for stocks in this situation carry wide confidence intervals, and early catalysts can shift them meaningfully. Verify all data at NSE and BSE before making any investment decision.
Scenario Analysis for Brooks Laboratories by 2030
Optimistic Case: Rs 67
The optimistic case for Brooks Laboratories by 2030 places the stock around Rs 67. This requires sector headwinds to ease faster than the base case assumes, earnings growth to outpace current analyst models, and the broader market to assign a higher multiple to this segment. These are analyst projections, not guaranteed outcomes.
Conservative Case: Rs 62
The conservative scenario extends the current headwinds further, landing around Rs 62 by 2030. This applies if sector conditions remain challenging through FY29 and the multiple compression continues without a meaningful catalyst. Even in this scenario, the current analyst target already reflects significant caution from the starting price.
| Scenario | Target 2030 | Return from CMP | What Changes It |
|---|---|---|---|
| Optimistic Case | Rs 67 | -6% | Sector headwinds ease faster than expected |
| Base Case | Rs 71.00 | +0% | Base-case gradual normalisation over 4 years |
| Conservative Case | Rs 62 | -13% | Headwinds persist beyond current analyst timeline |
What Could Change the Analyst View on Brooks Laboratories
Sector Catalyst Triggers Worth Monitoring
Analyst targets are living estimates. The factors driving current caution on Brooks Laboratories are primarily sector-level and macro in nature. A material improvement in any of the conditions described above would typically prompt a revision in the Brooks Laboratories share price target within one to two quarterly update cycles. Investors should watch sector-level earnings reports from Brooks Laboratories’s peers as leading indicators of whether the broader recalibration is turning.
Earnings Growth and Margin Recovery as Rerating Triggers
If Brooks Laboratories’s quarterly earnings consistently surprise on the upside relative to analyst estimates, that is typically the earliest signal that the conservative target model is being revised. Even one strong quarter can shift the narrative meaningfully. The Brooks Laboratories share price target for 2027 at Rs 47.00 is built on current run-rate assumptions; a material earnings beat changes that base.
How to Approach Brooks Laboratories as an Investor
Investors already holding Brooks Laboratories should monitor the sector-level indicators that the analyst caution is based on, specifically those outlined in the why section above. The Univest Screener provides live price alerts and quarterly result tracking for NSE ticker BROOKS. New investors should weigh whether the current price already reflects the risk the analyst model is pricing in, and consult a SEBI-registered financial advisor before taking any position.
Track This Stock Live on the Univest Screener
Conclusion
The Brooks Laboratories share price target of Rs 47.00 for 2027, Rs 54.00 for 2028, and Rs 71.00 for 2030 reflects a conservative analyst consensus on the diversified sector rather than any fundamental concern about Brooks Laboratories as a business. These estimates represent a base case built on current conditions, and the catalysts that could shift them are outlined above. Always verify financial data at NSE India and BSE India before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information and may not be accurate. Analyst targets are forward-looking estimates subject to significant uncertainty and should not be the sole basis for any investment decision. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Download the Univest iOS App or Univest Android App to track Brooks Laboratories share price live and get daily stock recommendations.
Frequently Asked Questions on Brooks Laboratories Share Price Target 2027 2028 and 2030
What is the Brooks Laboratories share price target for 2027?
Ans. The current analyst estimate for Brooks Laboratories in 2027 is Rs 47.00, which is approximately 34 percent below the current market price of Rs 70.95. This reflects conservative assumptions about near-term earnings growth in the diversified sector. Verify at NSE India before investing.
What is the Brooks Laboratories share price target for 2030?
Ans. The 2030 analyst estimate for Brooks Laboratories is Rs 71.00, approximately 0 percent below CMP. Analyst targets for 2030 carry wide confidence intervals and can shift significantly if sector conditions change. These are estimates, not guaranteed outcomes.
Why is the Brooks Laboratories share price target below the current price?
Ans. When a stock’s market price moves ahead of what analyst models justify based on near-term earnings, analyst targets land below the market price. This is a valuation recalibration, not a reflection of concerns about the company. The conditions driving this are discussed in detail above.
What is the Brooks Laboratories share price target for 2028?
Ans. The 2028 analyst estimate for Brooks Laboratories is Rs 54.00, approximately 24 percent below current levels. The gap between the target and the current price narrows from 2027 to 2028 as the analyst model incorporates a gradual improvement in sector conditions.
Should I sell Brooks Laboratories shares given these cautious targets?
Ans. Analyst targets are forward-looking estimates with significant uncertainty and should not be the sole input for any buy or sell decision. Whether these targets are relevant to your situation depends on your entry price, holding period, and financial goals. Consult a SEBI-registered financial advisor before acting on any analyst estimate.
What could change the analyst view on Brooks Laboratories?
Ans. Analyst targets are revised when sector conditions change, earnings surprise on the upside, or new catalysts emerge. The ‘Why Analysts Are Cautious’ section of this article outlines the specific factors that, if resolved earlier than expected, could prompt an upward revision.
What sector does Brooks Laboratories belong to?
Ans. Brooks Laboratories operates in the diversified sector. Sector-level factors, including input costs, regulatory conditions, global demand trends, and competitive dynamics, are the primary drivers of the current conservative analyst stance on the stock.
How can I track Brooks Laboratories share price?
Ans. You can track Brooks Laboratories live on the NSE using ticker BROOKS. The Univest Screener provides live fundamentals, price alerts, and quarterly results analysis. Always consult a SEBI-registered financial advisor before making any investment decision.
